Cyprotex PLC Launch of new Biosciences division
16 July 2015 - 4:00PM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
16 July 2015
Cyprotex launches new Biosciences division
16th July, 2015;
Cyprotex PLC (AIM:CRX), a specialist Contract Research
Organisation (CRO), announced today the launch of a new Biosciences
division to complement its existing ADME-Tox business.
The new Biosciences division enables customers to access
Cyprotex's expertise in 2D and 3D cell-based efficacy screening to
investigate the therapeutic or biological effect of new molecules.
These cell-based assays are developed using Cyprotex's experience
in techniques such as high content screening, microelectrode array,
and cellular bioenergetics. Cyprotex has already been involved in
developing several of these screening assays but, until now, has
not actively promoted them.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments:
'We are finding that customers are utilising our experience in
existing specialist technologies for efficacy based screening
activities. Introducing a Biosciences division is a natural
progression from ADME-Tox, allowing us to further diversify our
business without significant investment, and enabling us to expand
into a new customer base.'
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1000 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services as well as the new Biosciences division. The
acquisition of the assets and business of CeeTox in January 2014
has enabled Cyprotex to expand its range of services to target the
personal care, cosmetics and chemical industries. The Company's
core capabilities include high quality in vitro ADME screening
services, in vitro bioscience services, mechanistic toxicology and
high content toxicology screening services, including our
proprietary CellCiphr(R) toxicity prediction technology, predictive
modelling using PBPK and QSAR techniques, including Cloe(R) PK for
in vivo PK prediction, and a range of skin, ocular and endocrine
disruption services. For more information, see
www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGCGDRUBBBGUU
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024